Furthermore, the loss of Sestrin2 increased hepatic vulnerability to cholestatic liver injury, as assessed by serum ALT levels, fibrosis, and apoptosis (Fig. 8), suggesting that Sestrin2 is involved in protecting against cholestatic liver disease. Here, GPT is linked to digestive system neoplasm.